The present invention includes novel compounds containing heterocycles or azaheterocycles and fused phenylene or aza and cyano substituted variants thereof. These compounds may be useful as host materials for phosphorescent electroluminescent devices. In some embodiments, the invention includes compounds of Formula I: ##STR00001##

The present invention includes novel compounds containing heterocycles or azaheterocycles and fused phenylene or aza and cyano substituted variants thereof. These compounds may be useful as host materials for phosphorescent electroluminescent devices. In some embodiments, the invention includes compounds of Formula I: ##STR00001##

The present invention provides NOS inhibitors such as iNOS inhibitors, or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, hydrate, or isomer thereof, in any crystalline form or in amorphous form. The inhibitors include 1,1 or 1,2 substituted-ethyl carbamimido thioates, cyclic compounds substituted with a carbamimidoyl sulfanylethylphenyl group and a carbamimidoylsulfanyl group, compounds substituted with a carbamimidoyl sulfanylethyl phenylmethyl group, bis-carbamimidoylsulfanylethyl substituted compounds, 2-propoxypyridine derivatives, alkylamine or heteroalkylamine derivatives, n-aminoethyl n-phenyl amine derivatives, and saturated heterocyclic fused benzene derivatives. Pharmaceutical products comprising the NOS inhibitors such as iNOS inhibitors and the applications thereof in prophylaxis and/or treatment of inflammatory diseases, and proliferative diseases such as cancer including gastro-intestinal, colorectal, gynecological, pancreatic, head and neck, esophageal, breast, lung, and central nervous system tumors, among others, are also provided.

The present invention provides NOS inhibitors such as iNOS inhibitors, or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, hydrate, or isomer thereof, in any crystalline form or in amorphous form. The inhibitors include 1,1 or 1,2 substituted-ethyl carbamimido thioates, cyclic compounds substituted with a carbamimidoyl sulfanylethylphenyl group and a carbamimidoylsulfanyl group, compounds substituted with a carbamimidoyl sulfanylethyl phenylmethyl group, bis-carbamimidoylsulfanylethyl substituted compounds, 2-propoxypyridine derivatives, alkylamine or heteroalkylamine derivatives, n-aminoethyl n-phenyl amine derivatives, and saturated heterocyclic fused benzene derivatives. Pharmaceutical products comprising the NOS inhibitors such as iNOS inhibitors and the applications thereof in prophylaxis and/or treatment of inflammatory diseases, and proliferative diseases such as cancer including gastro-intestinal, colorectal, gynecological, pancreatic, head and neck, esophageal, breast, lung, and central nervous system tumors, among others, are also provided.

The present invention relates to compounds containing fused dibenzo more-than-six-membered heterocycles or azaheterocycles. These compounds may be useful as host materials for phosphorescent electroluminescent devices.

The present invention relates to compounds containing fused dibenzo more-than-six-membered heterocycles or azaheterocycles. These compounds may be useful as host materials for phosphorescent electroluminescent devices.

Provided is a compound having higher fluorescence quantum yield and higher optical stability than a conventional FLAP and a polymer compound containing the compound.

##STR00001## A: seven or eight-membered ring structure, Y.sup.1,Y.sup.2,Y.sup.3: halogen atom or the like, a1: number of Y.sup.1, a2: number of Y.sup.2, B: number of Y.sup.3, 0m and n3: when 1m3, Y.sup.1 may be substituted with a structure portion defined by m, when 1n3, Y.sup.2 may be substituted with a structure portion defined by n, and B.sup.1, B.sup.2: Formulas (2-1) to (2-3).

##STR00002## C.sup.1, C.sup.2, C.sup.3: structure containing a cyclic hydrocarbon compound, D.sup.1, D.sup.2, D.sup.3: substructure that inhibits aggregation, E.sup.1, E.sup.2, E.sup.3: polymerizable substructure, Z.sup.1: hydrogen atom or the like, c: number of substituent groups Z.sup.1, Z.sup.2, Z.sup.3: hydrogen atom or the like, and may form a ring with C.sup.2.

Provided is a compound having higher fluorescence quantum yield and higher optical stability than a conventional FLAP and a polymer compound containing the compound.

##STR00001## A: seven or eight-membered ring structure, Y.sup.1,Y.sup.2,Y.sup.3: halogen atom or the like, a1: number of Y.sup.1, a2: number of Y.sup.2, B: number of Y.sup.3, 0m and n3: when 1m3, Y.sup.1 may be substituted with a structure portion defined by m, when 1n3, Y.sup.2 may be substituted with a structure portion defined by n, and B.sup.1, B.sup.2: Formulas (2-1) to (2-3).

##STR00002## C.sup.1, C.sup.2, C.sup.3: structure containing a cyclic hydrocarbon compound, D.sup.1, D.sup.2, D.sup.3: substructure that inhibits aggregation, E.sup.1, E.sup.2, E.sup.3: polymerizable substructure, Z.sup.1: hydrogen atom or the like, c: number of substituent groups Z.sup.1, Z.sup.2, Z.sup.3: hydrogen atom or the like, and may form a ring with C.sup.2.

Provided are a photoactive fluorophore, a photoactive ligand, and a photoactive complex. The photoactive fluorophore includes a photoactivatable derivative of an azetidine-containing Janelia-Fluor dye. The photoactive ligand includes a photoactive fluorophore and a protein tag. The photoactive complex includes a photoactive ligand conjugated to a protein. Also provided are methods of in vivo labeling with and photoactivation of the photoactive fluorophore, ligand, and complex.

Provided are a photoactive fluorophore, a photoactive ligand, and a photoactive complex. The photoactive fluorophore includes a photoactivatable derivative of an azetidine-containing Janelia-Fluor dye. The photoactive ligand includes a photoactive fluorophore and a protein tag. The photoactive complex includes a photoactive ligand conjugated to a protein. Also provided are methods of in vivo labeling with and photoactivation of the photoactive fluorophore, ligand, and complex.